Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
$26.35
$26.35
$8.10
$26.73
$1.00B0.64145,059 shs716,706 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$51.13
+0.9%
$46.21
$28.72
$58.38
$4.05B0.52864,979 shs1.17 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$36.61
+0.6%
$35.50
$29.59
$60.37
$3.46B0.34840,220 shs759,203 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$34.22
-0.6%
$29.07
$21.51
$56.00
$4.12B11.44 million shs1.35 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
+3.81%+5.91%+1.48%-2.39%+35.43%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
+0.72%+3.76%-7.38%-10.94%-11.50%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+3.74%+13.38%+6.86%+16.45%+27.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
3.4034 of 5 stars
3.31.00.04.42.80.80.0
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
3.9133 of 5 stars
3.51.00.03.82.82.50.6
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.5354 of 5 stars
4.50.00.00.04.30.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
0.00
N/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.64
Moderate Buy$63.7524.68% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.92
Moderate Buy$88.77142.47% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.00
Buy$66.3893.99% Upside

Current Analyst Ratings Breakdown

Latest CMTA, PTCT, RNA, and RARE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
5/27/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.00
5/12/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$72.00 ➝ $68.00
5/9/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$55.00 ➝ $68.00
5/9/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.00
5/8/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$50.00 ➝ $40.00
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/AN/AN/AN/A$5.18 per shareN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.77B2.29$2.46 per share20.80($10.85) per share-4.71
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$590.69M5.86N/AN/A$2.76 per share13.26
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$8.93M461.99N/AN/A$6.76 per share5.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
-$58.13M-$7.93N/AN/AN/AN/A-44.73%-41.66%N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%8/14/2025 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$569.18M-$5.88N/AN/AN/A-101.60%-193.80%-38.15%7/30/2025 (Estimated)
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$212.22M-$3.00N/AN/AN/A-2,772.45%-27.66%-24.56%8/8/2025 (Estimated)

Latest CMTA, PTCT, RNA, and RARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
5/6/2025Q1 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
N/A
14.03
14.03
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
2.10
2.04
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.37
2.65
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
17.76
17.76
CompanyEmployeesShares OutstandingFree FloatOptionable
Clementia Pharmaceuticals Inc. stock logo
CMTA
Clementia Pharmaceuticals
3038.06 millionN/ANot Optionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million72.88 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,31094.54 million86.99 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
190120.52 million114.92 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Clementia Pharmaceuticals stock logo

Clementia Pharmaceuticals NASDAQ:CMTA

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$51.13 +0.44 (+0.87%)
As of 04:00 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$36.61 +0.21 (+0.58%)
As of 04:00 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$34.22 -0.19 (-0.55%)
As of 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.